Intra-arterial Iodine 131–Labeled Lipiodol as Adjuvant Therapy After Curative Liver Resection for Hepatocellular Carcinoma

Partensky, Christian; Sassolas, G.; Henry, Luc; Paliard, P; Maddern, Guy J.

doi:10.1001/archsurg.135.11.1298

Cited by 62 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overall recurrence was 30.1%, 62.3% and 79.0% in 1, 3, 5 years after resection of HCC, respectively [5] . Adjuvant therapies were used to prolong the survival and decrease the recurrence of HCC in different centers, such as transcatheter arterial chemoembolization (TACE) [6][7][8][9][10][11][12][13] , polyprenoic acid [14] , adoptive immunotherapy [15] , interferon [16] , and iodine-131-labeled lipiodol [17][18][19] . TACE was one of the most commonly used adjuvant managements for preventing recurrence and prolonging the survival of patients postoperatively.…”

Section: Introductionmentioning

confidence: 99%

Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: A retrospective control study

Ren

Lin²,

Xia³

et al. 2004

WJG

View full text Add to dashboard Cite

AIM:To evaluate the effect of postoperative adjuvant transcatheter arterial chemoembolization (TACE) on the prognosis of hepatocellular carcinoma (HCC) patients with or without risk factors for the residual tumor. METHODS:From January 1995 to December 1998, 549 consecutive HCC patients undergoing surgical resection were included in this research. There were 185 patients who underwent surgical resection with adjuvant TACE and 364 patients who underwent surgical resection only. Tumors with a diameter more than 5 cm, multiple nodules, and vascular invasion were defined as risk factors for residual tumor and used for patient stratification. Kaplan-Meier method was used to analyze survival curve and Cox proportional hazard model was used to evaluate the prognostic significance of adjuvant TACE. RESULTS:In the patients without any risk factors for the residual tumor, the 1-, 3-, 5-year survival rates were 93.48%, 75.85%, 62.39% in the control group and 97.39%, 70.37%, 50.85% in the adjuvant TACE group, respectively. There was no significant difference in the survival between two groups (P = 0.3956). However, in the patients with risk factors for residual tumor, postoperative adjuvant TACE significantly prolonged the patients' survival. There was a statistically significant difference in survival between two groups (P = 0.0216). The 1-, 3-, 5-year survival rates were 69.95%, 49.86%, 37.40% in the control group and 89.67%, 61.28%, 44.36% in the adjuvant TACE group, respectively. Cox proportional hazard model showed that tumor diameter and cirrhosis, but not the adjuvant TACE, were the significantly independent prognostic factors in the patients without risk factors for residual tumor. However, in the patients with risk factors for residual tumor adjuvant TACE, and also tumor diameter, AFP level, vascular invasion, were the significantly independent factors associated with the decreasing risk for patients' death from HCC. CONCLUSION:Postoperative adjuvant TACE can prolong the survival of patients with risk factors for residual tumor, but can not prolong the survival of patients without risk factors for residual tumor.Ren ZG, Lin ZY, Xia JL, Ye SL, Ma ZC, Ye QH, Qin LX, Wu ZQ, Fan J, Tang ZY. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: A retrospective control study.

show abstract

Section: Introductionmentioning

confidence: 99%

Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: A retrospective control study

Ren

Lin²,

Xia³

et al. 2004

WJG

View full text Add to dashboard Cite

show abstract

“…11 After this initial result several follow-up trials gave inconclusive results. [12][13][14] Nevertheless, the size of these trials was relatively small, and their clinical usefulness still needs confirmation in large multi-centre trials.…”

Section: Discussionmentioning

confidence: 99%

Recurrence and survival for hepatocellular carcinoma after curative resection: Tertiary centre experience

Li¹,

Cheung²

2008

Surgical Practice

View full text Add to dashboard Cite

Aim:The aim of the present paper was to determine the pattern of recurrence and prediction for survival after primary curative surgical resection of hepatocellular carcinoma (HCC). Methods: This was a retrospective single institutional review. During 2002During -2005 patients had hepatectomies at Queen Elizabeth Hospital The total number of patients with primary curative liver resection was 113, and 103 patients were included in this survival analysis. Results: The recurrence rate was 49/103 (47.6%). The operative mortality rate was 4/113 (3.5%). The median time for recurrence was 13.5 months (range, 1-60 months). The mean follow-up period was 26.03 months (range, 1-60 months).Overall survival was 90%, 72% and 50%, at 1, 3 and 5 years, respectively, and diseasefree survival was 55%, 48% and 42%, at 1, 3 and 5 years, respectively. On univariate analysis, tumour > 10 cm, close (Յ 1 mm)/focally involved/involved resection margin, operative blood loss > 2500 mL, presence of satellite tumour nodules, vascular invasion and poor tumour differentiation were found to be associated with recurrence. On multivariate analysis presence of multiple satellite tumour nodules and presence of vascular invasion predicted poor disease-free survival whereas vascular invasion was the only predictor for overall survival. Conclusion: Patients who had curative surgical resection for HCC should be considered for adjuvant therapy when these high-risk factors are present.

show abstract

“…30 These findings indicate that I-131-Lip has potential advantages for use in hepatoma therapy. [31][32][33] The selective delivery and retention of lipiodol are thought to result from the developed neovasculature, enhanced permeability and the poor reticuloendothelial systems observed in hepatoma tissues. Despite this capacity for the selective accumulation at the tumor site, clinical studies have shown the effectiveness of such I-131-Lip therapy alone to only be temporary, and early HCC recurrence was observed in many cases.…”

Section: Discussionmentioning

confidence: 99%

Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy

et al. 2005

View full text Add to dashboard Cite

Intra-arterial Iodine 131–Labeled Lipiodol as Adjuvant Therapy After Curative Liver Resection for Hepatocellular Carcinoma

Abstract: Intra-arterial lipiodol labeled with iodine 131 (131 I-lipiodol) can be safely used as adjuvant therapy following curative liver resection for hepatocellular carcinoma (HCC).

Cited by 62 publications

References 12 publications

Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: A retrospective control study

Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: A retrospective control study

Recurrence and survival for hepatocellular carcinoma after curative resection: Tertiary centre experience

Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy

Contact Info

Product

Resources

About